Higher dose hormone therapy aims to control rare calcium disorder

NCT ID NCT07081997

Recruiting now Disease control Sponsor: Ascendis Pharma Bone Diseases A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This phase 3 trial tests higher daily doses (over 30 mcg) of palopegteriparatide (Yorvipath) in 36 adults with chronic hypoparathyroidism. Participants already on the drug will have their dose adjusted to find the best level for controlling calcium without needing extra vitamin D or calcium supplements. The study lasts 78 weeks and focuses on safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palopegteriparatide (Yorvipath)
What this could lead to: If successful, this could provide a more effective way to manage hypoparathyroidism with higher doses, reducing the need for calcium and vitamin D supplements.
What could go wrong: This is a small, open-label trial with only 36 participants, so results may not apply broadly. Higher doses may also increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOCRINE SYSTEM DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine system disorder hypoparathyroidism parathyroid gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOCRINE SYSTEM DISEASES HYPOPARATHYROIDISM PARATHYROID DISEASES

Contacts and locations

Locations

Ascendis Pharma Investigational Site
RECRUITING

Reno, Nevada, 89511, United States
Ascendis Pharma Investigational Site
RECRUITING

New York, New York, 10032, United States
Ascendis Pharma Investigational Site
RECRUITING

Spokane Valley, Washington, 99216, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.